Daclatasvir Dihydrochloride
Tsanangudzo
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) ine simba uye inoshanda nemuromo.HCV NS5A proteininhibitor neEC50s siyana ye9-146 pM yeakawanda HCV replicon genotypes.Daclatasvir dihydrochloride iri zvakareorganic anion inotakura polypeptide 1B (OATP1B)uyeOATP1B3inhibitor neIC50s ye1.5 µM uye 3.27 µM, zvichiteerana.
IC50& Chinangwa
EC50: 50 pM (HCV replicon genotype 1a), 9 pM (HCV replicon genotype 1b), 71 pM (HCV replicon genotype 2a), 146 pM (HCV replicon genotype 3a), 12 pM (HCV replicon genotype 3 pM) uye (HCV replicon genotype 3 pM) HCV replicon genotype 5a)[1]
Kd: 8 nM (NS5A33-202) uye 210 nM (NS5A26-202)[2]
IC50: 1.5 µM (OATP1B) uye 3.27 µM (OATP1B3)[3]
In Vitro
Daclatasvir (BMS-790052) inoratidza zvine simba inhibitory chiitiko kune ese genotypes akaedzwa, neEC.50kukosha kubva pa9pm kusvika 146pm.Daclatasvir inhibits HCV replicon genotype 1a, 1b, 2a, 3a, 4a uye 5a ine EC50kukosha kwe50 pM, 9 pM, 71 pM, 146 pM, 12 pM uye 33 pM, zvichiteerana.Daclatasvir inhibitor ine simba yeJFH-1 genotype 2a hutachiona hwehutachiona hunodzokorora musero tsika (EC.50=28pm)[1].Daclatasvir (BMS-790052) inosunga zvakasimba kuNS5A33-202 uye NS5A26-202 neKds ye8 nM uye 210 nM, zvichiteerana[2].
Storage
| Upfu | -20°C | 3 years |
| 4°C | 2 years | |
| In solvent | -80°C | 6 mwedzi |
| -20°C | 1 mwedzi |
Clinical Muedzo
| Nhamba yeNCT | Sponsor | Condition | Zuva Rokutanga | Phase |
| NCT03369327 | Tehran University of Medical Sayenzi | RojanPharma Pharmaceutical Kambani | Hepatitis C Virus Infection, Response to Therapy ye|Human Immunodeficiency Virus | Ndira 1, 2017 | Phase 3 |
| NCT03485846 | R-Pharm|Almedis | Chisingaperi Hepatitis C Genotype 1b | Mbudzi 27, 2017 | Phase 2 |
| NCT01016912 | Bristol-Myers Squibb | Hepatitis C Infection | Zvita 2009 | Phase 2 |
| NCT01629732 | Bristol-Myers Squibb | Utachiona hweHepatitis C | Kurume 2013 | Phase 2 |
| NCT01497834 | Bristol-Myers Squibb | Hepatitis C | Ndira 2012 | Phase 3 |
| NCT01973049 | Bristol-Myers Squibb | Hepatitis C | Zvita 2013 | Phase 3 |
| NCT00663208 | Bristol-Myers Squibb | Chronic Hepatitis C | Chivabvu 2008 | Phase 2 |
| NCT02576314 | Humanity and Health Research Center|Beijing 302 Hospital | Chronic Hepatitis C Infection | Chivabvu 2015 | Phase 3 |
| NCT02756936 | Genuine Research Center, Egypt|Zeta Pharma Pharmaceutical Industries | Hutano | Kukadzi 2016 | Phase 1 |
| NCT02771405 | National Hepatology & Tropical Medicine Research Institute|Cairo University | Hepatitis C, Chisingaperi | Hepatocellular Carcinoma | Kurume 2016 | Phase 3 |
| NCT03706898 | Viriom | HIV-1-infection|Hepatic Impairment | Gumiguru 1, 2018 | Phase 1 |
| NCT02319031 | Bristol-Myers Squibb | Hepatitis C | Kukadzi 2015 | Phase 3 |
| NCT02124044 | National Institutes of Health Clinical Center (CC)|National Institute of Allergy uye Infectious Diseases (NIAID)|Bristol-Myers Squibb | HIV-HCV | Kukadzi 2014 | Phase 2 |
| NCT02551861 | Bristol-Myers Squibb | Hepatitis C | Zvita 2015 | Phase 2 |
| NCT00859053 | Bristol-Myers Squibb | Hepatic Insufficiency | Kurume 2009 | Phase 1 |
| NCT01257204 | Bristol-Myers Squibb | Utachiona hweHepatitis C | Zvita 2010 | Phase 2 |
| NCT03063879 | Tehran University of Medical Sciences|Ahvaz Jundishapur University of Medical Sayenzi|Shiraz University of Medical Sayenzi|Hamadan University of Medical Science | Chirwere cheHepatitis C, Chisingaperi|Kutadza Kwerenal Kusingaperi | Kubvumbi 1, 2017 | Chikamu chechina |
| NCT01017575 | Bristol-Myers Squibb | Hepatitis C Infection | Zvita 2009 | Phase 2 |
| NCT02865369 | Sang Gyune Kim|Seoul National University Boramae Hospital|Severance Hospital|Inha University Hospital|Korea University|Gachon University Gil Medical Center|Hanyang University Seoul Hospital|Ewha Womans University Mokdong Hospital|Bristol-Myers Squibb|Soonchunhyang University Hospital | Chronic Hepatitis C | Gunyana 2016 |
|
| NCT04070235 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Hepatitis C, Chisingaperi | Kurume 29, 2019 | Chikamu 2 | Phase 3 |
| NCT03487848 | Bristol-Myers Squibb | Hepatitis C | Chisingaperi Hepatitis | Chivabvu 18, 2018 | Phase 2 |
| NCT00904059 | Bristol-Myers Squibb | Hepatitis C | Chivabvu 2009 | Phase 1 |
| NCT02107365 | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Infection | Mbudzi 2013 | Phase 2 |
| NCT02397395 | Janssen R&D Ireland | Renal Impairment | Kupera-nhanho Renal Chirwere | Chivabvu 2015 | Phase 2 |
| NCT03169348 | Assiut University | Hepatitis C | Mbudzi 1, 2017 | Hazvigoneke |
| NCT02323594 | Bristol-Myers Squibb | Hepatitis C Infection | Zvita 2014 | Phase 1 |
| NCT03537196 | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | Hepatitis C | Kushandisa Zvinodhaka|Viral Hepatitis C | Mbudzi 13, 2018 | Chikamu chechina |
| NCT02103569 | Bristol-Myers Squibb | Hepatitis C | Kubvumbi 2014 | Phase 1 |
| NCT02772744 | Zagazig University | Cairo University | Hepatitis C | Mbudzi 1, 2017 |
|
| NCT01718158 | Bristol-Myers Squibb | Hepatitis C | Ndira 2013 | Phase 3 |
| NCT02496078 | Bristol-Myers Squibb | Hepatitis C | Nyamavhuvhu 2015 | Phase 3 |
| NCT01425970 | Bristol-Myers Squibb | Hepatitis C | Chivabvu 2012 | Phase 2 |
| NCT01471574 | Bristol-Myers Squibb | Hepatitis C, Genotype 1 | Zvita 2011 | Phase 3 |
| NCT01573351 | Bristol-Myers Squibb | Utachiona hweHepatitis C | Chivabvu 2012 | Phase 3 |
| NCT01938625 | Janssen R&D Ireland | Hepatitis C, Chisingaperi | Zvita 12, 2013 | Phase 2 |
| NCT01492426 | Bristol-Myers Squibb | Hepatitis C | Ndira 2012 | Phase 3 |
| NCT03480932 | Johns Hopkins Bloomberg School of Public Health|National Institute on Drug Abuse (NIDA)|YR Gaitonde Center yeAIDS Research and Education | Hepatitis C, Chisingaperi | Kukadzi 2, 2018 | Chikamu 2 | Phase 3 |
| NCT03163849 | Assiut University | Chirwere Chisingaperi c | Gunyana 1, 2019 | Phase 3 |
| NCT01581203 | Bristol-Myers Squibb | Utachiona hweHepatitis C | Chivabvu 2012 | Phase 3 |
| NCT01492504 | Bristol-Myers Squibb | Hepatitis C | Kukadzi 7, 2012 |
|
| NCT03686722 | Mohamed Raslan|Ain Shams University|Drug Research Center, Cairo, Egypt | Diabetes Mellitus, Type 2|Hepatitis C|Kudyidzana Kwezvinodhaka | Gunyana 9, 2017 | Phase 1 |
| NCT02262728 | Janssen Research & Development, LLC | Hepatitis C, Chisingaperi | Gunyana 30, 2014 | Phase 2 |
| NCT02349048 | Janssen Research & Development, LLC | Utachiona hweHepatitis C | Ndira 2015 | Phase 2 |
| NCT03882307 | Assiut University | Hepatitis C, Chisingaperi | Chivabvu 2020 | Early Phase 1 |
| NCT02758509 | Parc de Salut Mar | Chronic Hepatitis C | Cirrhosis | Ndira 1, 2010 |
|
| NCT01795911 | Bristol-Myers Squibb | Hepatitis C | Kurume 2013 | Phase 2 |
| NCT03549832 | Assiut University | Sohag University | South Valley University | HCV Coinfection | Ndira 1, 2018 | Hazvigoneke |
| NCT02161939 | Bristol-Myers Squibb | Chronic Hepatitis C |
| |
| NCT01309932 | Bristol-Myers Squibb | Hepatitis C | Kurume 2011 | Phase 2 |
| NCT01995266 | Bristol-Myers Squibb | Hepatitis C | Kukadzi 28, 2014 | Phase 3 |
| NCT02640157 | AbbVie | Chronic Hepatitis C|Hepatitis C Virus|Genotype 3 Hepatitis C Virus | Zvita 2015 | Phase 3 |
| NCT02032875 | Bristol-Myers Squibb | Hepatitis C | Kurume 2014 | Phase 3 |
| NCT02624063 | Federal University yeSão Paulo | Hepatitis C, Chisingaperi | Zvita 2015 | Chikamu chechina |
| NCT00546715 | Bristol-Myers Squibb | Chronic Hepatitis C | Mbudzi 2007 | Chikamu 1 | Chikamu 2 |
| NCT01718145 | Bristol-Myers Squibb | Hepatitis C Virus Infection | Mbudzi 2012 | Phase 3 |
| NCT01616524 | Bristol-Myers Squibb | Utachiona hweHepatitis C (HCV) | Chikunguru 2012 | Phase 3 |
| NCT02032901 | Bristol-Myers Squibb | Hepatitis C | Ndira 2014 | Phase 3 |
| NCT03540212 | Ain Shams University | Chisingaperi HCV Utachiona | Zvita 10, 2017 | Chikamu 2 | Phase 3 |
| NCT02097966 | Bristol-Myers Squibb | Chronic Hepatitis C |
| |
| NCT02596880 | Tehran Yunivhesiti yeMedical Sayenzi | Hepatitis C | Cirrhosis | Gunyana 2015 | Phase 3 |
| NCT04019717 | Nhoroondo ye Atea Pharmaceuticals, Inc. | Hepatitis C|Hepatitis C, Chisingaperi|Chisingaperi Hepatitis C|Hepatitis C Virus Infection|HCV Infection | Chikumi 20, 2019 | Phase 2 |
| NCT02992457 | Tanta University | Hepatitis C | Ndira 2015 | Chikamu chechina |
| NCT03547895 | Zagazig University | Decompensated Cirrhosis | Chikumi 1, 2015 | Hazvigoneke |
| NCT03004625 | Kaohsiung Medical University Chung-Ho Memorial Hospital|Chang Gung Memorial Hospital|National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|China Medical University Hospital|National Cheng-Kung University Hospital | Hepatitis C | Mbudzi 2016 | Phase 3 |
| NCT01051414 | Bristol-Myers Squibb | Hepatitis C Infection | Kubvumbi 2010 | Phase 2 |
| NCT02309450 | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Infection | Zvita 2014 | Phase 2 |
| NCT01628692 | Bristol-Myers Squibb|Janssen Research & Development, LLC | Utachiona hweHepatitis C | Chikunguru 2012 | Phase 2 |
| NCT03186313 | Chipatara cheEgyptian Chipatara | Wadi El Nil Hospital | Hepatitis C | Gunyana 2016 | Phase 3 |
| NCT03063723 | Chipatara chechitatu chakabatana, Sun Yat-Sen University | Chisingaperi Hepatitis C (Chirwere) | Ndira 1, 2016 |
|
| NCT00983957 | Bristol-Myers Squibb | Chronic Hepatitis C | Gumiguru 2009 | Phase 1 |
| NCT01725542 | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | HCV-HIV Co-Infection | Zvita 2012 | Phase 2 |
| NCT02282709 | Nheyo yeKutsvaga Chiropa | Chronic Hepatitis C | Kukadzi 2014 | Phase 3 |
| NCT02032888 | Bristol-Myers Squibb | Hepatitis C | Kukadzi 2014 | Phase 3 |
| NCT03247296 | MTI University | Hepatitis C | Kukadzi 28, 2017 |
|
| NCT01389323 | Bristol-Myers Squibb | Hepatitis C | Gunyana 2011 | Phase 3 |
| NCT02556086 | Bristol-Myers Squibb | Hepatitis C | Zvita 2015 | Phase 2 |
| NCT01741545 | Bristol-Myers Squibb | Utachiona hweHepatitis C | Kurume 31, 2013 | Phase 3 |
| NCT01866930 | Bristol-Myers Squibb | Chronic Hepatitis C Infection | Chikunguru 11, 2013 | Phase 3 |
| NCT02268864 | Nhoroondo ye Janssen-Cilag International NV | Hepatitis C, Chisingaperi | Ndira 2015 | Phase 2 |
| NCT01797848 | Bristol-Myers Squibb | Hepatitis C | Chikumi 2014 | Phase 3 |
| NCT03166280 | Eman Sayed Hassan Abd Allah|Assiut University | Hepatitis C | Chikumi 2017 |
|
| NCT02159352 | Bristol-Myers Squibb | Hepatitis C | Chikumi 2014 | Phase 1 |
| NCT01125189 | Bristol-Myers Squibb | Utachiona hweHepatitis C | Chikunguru 2010 | Phase 2 |
| NCT03748745 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Kudyidzana Kwezvinodhaka | Mbudzi 19, 2018 | Phase 1 |
| NCT01012895 | Bristol-Myers Squibb | Chronic Hepatitis C | Zvita 2009 | Phase 2 |
| NCT02565888 | Radboud University | Hepatitis C | HIV | Mbudzi 2015 | Phase 1 |
| NCT02555943 | Humanity and Health Research Center|Beijing 302 Hospital|Nanfang Hospital yeSouthern Medical University | Chronic Hepatitis C Infection|HBV Coinfection|Hepatitis B Reactivation | Kukadzi 2015 | Chikamu 2 | Phase 3 |
| NCT02304159 | Tarek I. Hassanein, MD, FACP, FAG, AGAF|Southern California Research Center | Hepatitis C | Cirrhosis | Ndira 2015 | Chikamu chechina |
| NCT02580474 | Myeong Jun Song|Bristol-Myers Squibb|Soonchunhyang University Hospital|Dankook University|Chungnam National University Hospital|Konyang University Hospital|Eulji University Hospital|Saint Vincent's Hospital, Korea|Konkuk University Hospital|Cheongju St. Mary's Hospital, Cheongju , Korea|Chipatara cheSeverance|Korea University Guro Hospital|Eulji General Hospital|The Catholic University of Korea | Hepatitis C | Kukadzi 2016 | Chikamu chechina |
| NCT02104843 | Bristol-Myers Squibb | Hepatitis C | Kubvumbi 2014 | Phase 1 |
| NCT01428063 | Bristol-Myers Squibb | Hepatitis C Virus Infection | Gunyana 2011 | Phase 2 |
| NCT02123654 | Bristol-Myers Squibb | Hepatitis C Virus Infection | Kubvumbi 2014 | Phase 3 |
| NCT02565862 | Radboud University | Hepatitis C | Chirwere cheshuga mellitus | Kuramba insulin | Ndira 2016 | Phase 1 |
| NCT04211844 | Ain Shams University | Chronic Hepatitis C | Gumiguru 1, 2019 |
|
| NCT00874770 | Bristol-Myers Squibb | Hepatitis C Infection | Chikumi 2009 | Phase 2 |
| NCT03883698 | Sanjay Gandhi Postgraduate Institute yeMedical Sayenzi | Kutadza kweitsvo, Kusingaperi|Hepatitis C | Kurume 15, 2019 | Phase 3 |
| NCT01448044 | Bristol-Myers Squibb | Hepatitis C | Zvita 2011 | Phase 3 |
| NCT01359644 | Bristol-Myers Squibb|Pharmasset | Chronic Hepatitis C | Chikumi 2011 | Phase 2 |
| NCT01842451 | Vertex Pharmaceuticals Incorporated | Chronic Hepatitis C|CHC|HCV|Hepatitis C | Chikumi 2013 | Phase 2 |
| NCT02762448 | Tainan Municipal Hospital | Hepatitis c | Chikunguru 2016 |
|
| NCT02473211 | Humanity and Health Research Center|Beijing 302 Hospital | Chronic Hepatitis C Infection | Ndira 2015 | Chikamu 2 | Phase 3 |
| NCT01455090 | Bristol-Myers Squibb | Chronic Hepatitis C | Mbudzi 30, 2011 | Phase 2 |
| NCT03490097 | Ain Shams University | Chronic Hepatitis c|Metabolic Syndrome | Zvita 1, 2017 | Chikamu 2 | Phase 3 |
| NCT01170962 | Bristol-Myers Squibb | Utachiona hweHepatitis C | Nyamavhuvhu 2010 | Phase 2 |
| NCT02333292 | Valme University Hospital|Chipatara del SAS de Jerez|Chipatara General Universitario Elche|Chipatara La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Hospital de Figueres|Chipatara Universitario Puerto Real|Chipatara Universitario Virgen de laversitari Hospital General Universitario de Alicante|Chipatara Universitario Araba|Chipatara Royo Vilanova|Chipatara Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Chipatara Universitario Reina Sofia de Cordoba|Chipatara Universitario Virgen Macarena Universidad de Universitario Navarra|Hospital Clinico Universitario San Cecilio|Chipatara Universitario La Fe|Chipatara General Universitario de Valencia|Chipatara Universitario Infanta Leonor|Chipatara Universitario de Gran Canaria|Chipatara General Universitario La Fe|Chipatara General Universitario de Valencia|Chipatara Universitario Infanta Leonor|Chipatara Universitario de Gran Canaria|Chipatara General Universitario Santa Lucía|Centro Penitenciario Hospital Alicante ne LUz|Chipatara General Universitario de Castellón|Chipatara Parc Taulí, Sabadell | Chronic Hepatitis C Infection | Zvita 2014 |
|
| NCT03200184 | Tehran Yunivhesiti yeMedical Sayenzi | Hepatitis C | Gunyana 1, 2016 | Chikamu chechina |
| NCT03188276 | Chipatara chechitatu chakabatana, Sun Yat-Sen University | Chronic Hepatitis C | Kukadzi 1, 2016 | Early Phase 1 |
| NCT01830205 | Bristol-Myers Squibb | Hepatitis C | Gunyana 2012 | Phase 1 |
Proposal18Quality Consistency Evaluation mapurojekiti akatenderwa4,uye6mapurojekiti ari pasi pekubvumidzwa.
Yepamberi yepasirese yemhando manejimendi system yakaisa hwaro hwakasimba hwekutengesa.
Kutariswa kwemhando yepamusoro kunofamba kuburikidza nehupenyu hwese kutenderera kwechigadzirwa kuti ive nechokwadi chemhando nekurapa.
Professional Regulatory Affairs timu inotsigira zvinodiwa zvemhando panguva yekushandisa uye kunyoreswa.
Korea Countec Bottled Packaging Line
Taiwan CVC Bottled Packaging Line
Italy CAM Board Packaging Line
German Fette Compacting Machine
Japan Viswill Tablet Detector
DCS Control Room
Kudyidzana kwenyika dzose
Kushandira pamwe kwemumba
Nyora meseji yako pano uye utumire kwatiri
